Latitude, Seasonality, and Circadian Determinants of Outcomes of Systemic Cancer Therapy: Evidence from Chemotherapy, Immunotherapy, and Chemo-Immunotherapy Combinations. A Systematic Review.
Aug 2026· Critical reviews in oncology/hematology· Vol 226, pp.
105509
· 0 citations· 47 references
Medicine
TL;DR
Time-of-day of treatment, seasonality, latitude-related sunlight exposure, vitamin D status, and circadian rhythm integrity are potentially relevant determinants of systemic therapy outcomes.
Abstract
Objectives
To evaluate whether treatment timing (chronotherapy/time-of-day infusion), seasonality, geographic latitude, and related vitamin D status are associated with efficacy and toxicity outcomes of systemic therapy for solid tumors.
STUDY
Design
PRISMA 2020-guided systematic review with qualitative synthesis.
Methods
PubMed/MEDLINE, Embase, Web of Science, and Scopus were searched from inception to January 20, 2026, with additional screening of oncology conference proceedings and trial registries. Eligible studies included randomized trials, observational cohorts, and meta-analyses assessing treatment timing, season/latitude proxies (including serum 25-hydroxyvitamin D), and/or objective circadian disruption, with outcomes including overall survival (OS), progression-free survival (PFS), response, and treatment-related toxicity. Two reviewers independently screened and extracted data using a predefined form. Risk of bias was assessed using Cochrane RoB 2.0 and the Newcastle-Ottawa Scale. Because of substantial clinical and methodological heterogeneity, findings were synthesized qualitatively and stratified by exposure domain and study design.
Results
Thirty-five studies were included (6 randomized trials, 2 patient-level meta-analyses, 5 prospective cohorts, 22 retrospective cohorts). Chronomodulated chemotherapy consistently reduced toxicity and sometimes improved response/time-to-progression, but survival effects were heterogeneous and appeared sex-dependent. Earlier immune checkpoint inhibitor administration (morning/early daytime) was associated with longer OS/PFS in mostly retrospective cohorts; these findings should therefore be considered hypothesis-generating pending prospective confirmation. Seasonal and latitude analyses generally showed worse outcomes in winter and at higher latitudes, although ecological and observational designs limited causal inference. Higher vitamin D levels and supplementation during immunotherapy were associated with improved survival but may partly reflect baseline health status and other prognostic factors. Objective circadian disruption was repeatedly associated with poorer prognosis.
Conclusions
Time-of-day of treatment, seasonality, latitude-related sunlight exposure, vitamin D status, and circadian rhythm integrity are potentially relevant determinants of systemic therapy outcomes. Evidence is strongest for chemotherapy chronomodulation in selected historical randomized trials, whereas immunotherapy timing, seasonal/latitude effects, and vitamin D associations remain less causally established. Prospective randomized studies should test pragmatic interventions such as structured ICI scheduling and vitamin D assessment/correction before routine implementation.
Adjunctive metformin did not improve overall or PFS but was associated with a higher ORR, driven by increased complete responses, without increasing high-grade toxicity, without increasing high-grade toxicity.
Bushra Wadi Bin Saddiq, Ahmed Salah Morad, T. Khan et al.· Frontiers in Oncology· 0 citations
Introduction To quantify overall-survival effects of immune-checkpoint-inhibitor (ICI)-containing regimens by treatment line and to evaluate whether clinical characteristics or PD-L1 definitions modify relative treatment benefit in advanced esophageal squamous cell carcinoma (ESCC). Methods PubMed, Embase, the Cochrane...
Background: Biologic therapies have transformed Thyroid Eye Disease (TED) management, but their comparative efficacy, safety, durability and effects on subsequent rehabilitative surgery remain uncertain.
Objective: To evaluate the efficacy and safety of teprotumumab, rituximab and tocilizumab across TED phenotypes and...
N. Yadav, Shimpa Kundan, Swati Singh et al.· Journal of Ophthalmology and...· 0 citations
Background Immune checkpoint inhibitors combined with chemotherapy have improved pathological responses in early-stage triple-negative breast cancer (TNBC), but the magnitude of benefit and associated toxicity remain variable across trials. This systematic review and meta-analysis aimed to evaluate the efficacy and saf...
Jia-Le Li, Pei-Tao Wu, Jing-Shu Song et al.· Frontiers in Oncology· 0 citations
Pretreatment body mass index (BMI) has been associated with outcomes during immune checkpoint inhibitor (ICI) therapy, but study-specific categories and incomplete adjustment complicate interpretation. We evaluated associations with efficacy and toxicity across tumor types and BMI definitions.
We searched...
Si-Yu Sun, Jun-Hao Zhang, Yan Li et al.· Frontiers in Immunology· 0 citations
Background First-line chemoimmunotherapy has become a major therapeutic strategy for advanced gastric and gastroesophageal junction cancer, yet the magnitude of survival benefit, regional consistency, and toxicity trade-offs remain important considerations. We conducted an systematic review and meta-analysis of randomi...
Xiao Zeng, Jia-Xi Chen· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.